Is Relay Therapeutics a Buy After Promising Trial Results?

Relay Therapeutics reported promising phase 2 data for zovegalisib, with about 60% volumetric response across 20 patients in vascular anomalies, broadening the drug's potential beyond oncology. The company also has roughly $642 million in cash, which management says can fund operations well into 2029, reducing financing risk. Offsetting that, Relay remains pre-revenue and highly dependent on zovegalisib, while analysts expect 2026 revenue of just $9.84 million and losses of about $1.64 per share.

Analysis

The market is starting to re-rate RLAY from a single-asset “hope story” into a platform with optionality, but the real second-order effect is that positive vascular-anomaly data expands the drug’s commercial pathway without materially changing the binary nature of the stock. That matters because rare-disease expansion can create an earlier, more measurable revenue bridge, which should lower the discount rate applied to the 2027 phase 3 setup; however, the valuation is still dominated by the next couple of readouts, not the distant pipeline.

The bigger competitive implication is for PI3Kα-adjacent assets more broadly: stronger differentiation in a safer or broader mutation spectrum can pressure rival programs to compete on tolerability, not just efficacy. If physicians begin viewing the asset as usable across oncology plus selected vascular indications, uptake could be faster than typical oncology launches because the prescribing narrative becomes mechanism-led rather than tumor-specific.

The main risk is that the current move can easily outrun evidence density. A 20-patient signal is enough to reset sentiment, but it is not enough to de-risk payer, durability, or class-toxicity concerns; any hint of edema, hyperglycemia, or discontinuation in larger cohorts would quickly compress the multiple again. With cash runway extending multiple years, financing risk is low, so the stock’s next 6-12 month tape should be driven almost entirely by data cadence rather than balance-sheet anxiety.

Consensus may be underestimating how much the Pfizer collaboration de-risks execution versus commercial economics: the partnership reduces development burden, but it also means upside could be less vertically integrated than bulls expect. In practice, that makes the cleanest bull case a data-driven re-rating into phase 3 initiation rather than a long-term monopoly thesis. I would treat the current rally as a momentum confirmation, not a full fundamental inflection.

Key Decisions for Investors

• Go long RLAY on pullbacks over the next 2-6 weeks, but size as a catalyst trade rather than a core biotech holding; upside is tied to the next clinical update cycle, while downside remains large on any safety or durability miss.
• Use call spreads in RLAY instead of outright stock for the 3-9 month window; the setup offers asymmetric upside into phase 3 initiation, but options cap risk if the market has already priced most of the near-term good news.
• Pair long RLAY / short a basket of less differentiated PI3K-pathway names over 1-2 quarters; the better readout quality here should compress relative valuation gaps if data remain clean.
• If RLAY gaps another 10-15% on no fresh data, trim into strength and wait for the next structured catalyst; the probability-weighted risk/reward deteriorates after sharp post-data re-ratings.
• Avoid treating PFE as a direct winner here; the collaboration is execution-positive but too small to move the needle, so any position should be based on broader pharma allocation, not this program-specific read-through.